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What is an animal growth promotant? This is a collective term not re-
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stricted to products of biotechnology which includes a number of dif-
ferent strategies to increase the rate and efficiency of animal product 
formation (eggs, meat, milk and wool). The following is offered as a 
contemporary definition as viewed by those involved in animal pro-
duction research: Growth promotants—strategies to increase the rate 
and efficiency of animal product formation with improved composi-
tion and desirability by the consuming public, free from harmful resi-
dues and environmentally neutral. Unfortunately a very negative per-
ception exists, particularly with reference to somatotropin, and this 
negativism is due to misinformation widely distributed in the popular 
press. Granted, anabolic steroids are considered a growth promotant; 
however, anabolic steroids are not restricted to diethylstilbesterol 
(DES). In fact, DES is now removed from use in production agriculture 
Strategies to use naturally occurring compounds and mimics in low 
supplemental levels have been developed to meet the above definition.
As an attempt to clarify the public perception of what constitutes a 
growth promotant, the following classification is offered:
Metabolic modifiers 
—* beta andregenec agonists;
—* somatotropin 
—* transgene manipulations 
—anabolic (steroid-like mimics) implants 
—enhancer of futile energy cycles 
—* immunomodulation
Extrasomatic Modifiers 
—antibiotics and probiotics 
—anticoccidiostats 
—anthelmintics.
Management Strategies 
—restricted feeding
— compensatory growth
— rearing the intact male 
—forage feeding systems.
Strategies vary with livestock species, clearly global geography and 
conditions of local legislation, as apparent in the U.S. Again, public 
perception is that growth promotants are used by the agricultural sec-
tor to the advantage of the livestock producer with blatant disregard 
for public welfare and the environment. Bringing a compound from 
the laboratory bench to the marketplace involves the approval of a very 
intricate mechanism of “checks and balances".
CHECKS AND BALANCES
During the initial research and development phase of a compound, 
the first check would fall to the ethics of the investigator. After initial 
discovery, questions are considered such as: Are the undesirable side 
effects noted in the use of the compound in the target species? Does 
the compound demonstrate selectivity with respect to the endpoint 
desired? Can the results be replicated at other locations? Is the com-
pound worthy of commercialization? Amazingly, few compounds sur-
vive beyond the initial discovery stage and most are dropped.
Scientists, either in the public or private research sector, operate by 
stringent rules and regulations. These include institutional research, 
animal care committees that review experimental protocols for com-
pliance to formal and informal guidelines, as established by fund 
granting agencies such as the U.S. Department of Agriculture (USDA) 
and the National Institutes of Health (NIH), and professional peer 
review of results submitted for publication. Due to recognized defi-
ciencies in some environments, most research institutions in the U.S. 
are striving for uniformity by adopting standards such as those pro-
posed by the American Association of Laboratory Animal Science.
(‘designates developments collectively referenced as “biotechnology” 
advances. At present none are approved beyond use in a research 
environment or in controlled field tests.)
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Following the discovery phase, a compound may survive into the 
marketing phase, and checks and balances at this stage are more famil-
iar to the public. As pertinent to animal agriculture, The Center for 
Veterinary Medicine of the Food and Drug Administration (FDA) has 
the primary responsibility for the new drug application review process. 
The Food Safety Inspection Service (FSIS) would have jurisdiction for 
the introduction of transgenic products into the food chain. The Ani-
mal and Plant Health Inspection Service (APHIS) regulates, in part, the 
use of animal biologies, transportation of transgenic products and sur-
veillance monitoring. Approximately 14 Federal agencies interact and 
regulate the marketing and use of agricultural chemicals.
Public watchdog organizations operate at both the discovery and 
marketing phases of a compound. These include consumer and envi-
ronmental activist groups which pose queries often resulting in legiti-
mate research investigations. Other activist organizations raise issues 
concerning the ethics of animal research. This offers yet another level 
180          of “checks and balances". Unfortunately, an impasse is often encoun-
tered, because despite all attempts to recognize and improve animal 
welfare considerations, those involved in animal production find the 
issue of “animal rights” contrary to desires or “rights” of mankind.
EXAMPLE: PORCINE SOMATOTROPIN
To address the topic of animal growth promotants, porcine somatotro-
pin (PST) was selected. Investigational PST is a mimic of the 191 ami-
no acid protein naturally secreted by the anterior pituitary and is pri-
marily involved with nitrogen metabolism and long bone growth. Por-
cine somatotropin is produced by recombinant DNA technology and is 
available in considerable quantities for research purposes through sev-
eral companies seeking registration approval. The impetus to examine 
PST efficacy relates to a very specific problem of the pork industry. 
Biomedical recommendation has advised the public to reduce the in-
take of animal fat, particularly saturated fatty acids, to reduce the risk 
of developing coronary artery disease. Pork is commonly believed to be 
a fatty meat and therefore some regard it as unhealthful. In part, this 
may explain why per capita pork consumption has remained static for 
about 20 years. As part of a larger issue, recommendations to re-duce 
human lipid consumption from the current figure of 38 percent of to-
tal caloric intake to 30 percent will require the composition of meat to 
be altered dramatically. Growth promotants, specifically those which 
alter nutrient partitioning exemplified by PST, may provide livestock 
agriculture the means to adjust commodity production to benefit pub-
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lie health. Animal product consumption provides the human popula-
tion with a large portion of high quality protein and several important 
vitamins and minerals; therefore, lowering the contribution fat intake 
derived from animal products is a worthy undertaking.
Based on several dozen research reports, PST can reliably improve the 
rate of body weight gain by approximately 10-15 percent in growing 
hogs, reduce the quantity of feed required per unit of body weight gain 
by 25 percent, increase edible meat yield by 5-10 percent and reduce fat 
deposition of hogs by 40-80 percent, depending on the dosage. Volun-
tary feed intake has consistently been reported to be reduced by 10 per-
cent as a result of PST treatment. These effects are consistent with the 
classification of PST as a nutrient partitioning agent and are not ma-
gic. Mechanistically PST is altering intermediary metabolism such 
that the hog is metabolically much younger. The carcass composition 
changes desired by the consumer are realized by improved production 
efficiency; therefore, producer adoption should occur quickly. Rather 
than create a pharmacolic milieu to alter growth patterns, PST repre-
sents a biological strategy permitting the animal to more fully express 
the genetic potential for lean tissue growth.
ENVIRONMENTAL SAFETY
The current decade was viewed as one of concern and action with res-
pect to environmental quality. Some countries in Europe have enacted 
legislation in an attempt to minimize the environmental impact of 
technological advances. The Netherlands serves as an example. A coun-
try approximately the size of the state of New Jersey has a human pop-
ulation of 14 million and a swine population of 20 million. This live-
stock population requires 102,000 tons of nitrogen for feed purposes 
per year. Currently, standards have been established to impose an en-
vironmental impact tax on nitrogen and phosphorous as pollutants. 
Based only on the improvement in feed conversion efficiency, PST 
would reduce nitrogen pollution by approximately 3,600 tons annu-
ally. Phosphorous loss to the environment would decrease by a similar 
magnitude, but other strategies such as the use of phytase in the feed 
may be of greater consequence. In itself, PST would not correct all is-
sues associated with environmental quality, but as part of a larger 
integrated strategy this growth promotant may contribute to the im-
provement of the environment. Intensive animal production manage-
ment systems as found in The Netherlands, Iowa and Illinois could 
benefit indirectly from this technological advancements
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HUMAN SAFETY
Somatotropins are extremely species-specific and follow a phylogenic 
hierarchy of biological activity such that PST would not have biologi-
cal activity in the human, whereas human somatotropin would be ac-
tive in hogs. Residues of the peptide, should they exist, would be dena-
tured during the cooking process of treated pork and further degrada-
tion would occur in the digestive tract of humans. These factors all 
contribute to the conclusion that PST as a residue would not pose a 
threat to the human population. However, the perception of biologi-
cally active residue(s) persists.
Based on research data reviewed in several manuscripts, increased 
levels of PST resulting from treatment is cleared from the circulation 
in 15 hours following administration. Using validated assay methods, 
PST has not been detected in the meat of treated animals. Treatment 
of young growing hogs enhances rate and efficiency of body weight 
gain. Furthermore, withdrawal from treatment does not result in a de-
compensation of beneficial effects; therefore, a sustained beneficial ef-
fect can be realized long after treatment withdrawal. This would per-
mit a lengthy withdrawal period prior to the marketing of treated pork 
should regulatory approval mandate.
On the proactive side, cardiovascular disease is the leading cause of 
mortality in industrialized societies and the biomedical community 
has concluded that this mortality is largely caused by the consumption 
of saturated fats in excess quantities mainly from animal products.
Use of PST would allow the production of extremely lean animals and 
trimmed pork as a commodity would be approximately five percent 
lipid. Intramuscular lipid concentration of fresh pork is small com-
pared to other meats. By substantially reducing the lipid content of 
pork, PST may reverse the public image of pork as a fatty and, there-
fore, unhealthful product.
TARGET ANIMAL SAFETY
An inherent joint problem in swine which relates to stiffness and feet 
and leg problems is known as osteochondrosis. Porcine somatotropin, 
possibly by accelerating rate of growth, was associated with an in-
crease in the incidence of this problem in early experiments. Subse-
quently, adjustment of the dietary calcium and phosphorous concen-
tration has greatly reduced this problem.
Unlike the dairy animal treated with bovine somatotropin (BST), 
hogs treated with PST have a narrow window of response, or dose res-
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ponse range. This means that there is approximately a fivefold differ-
ence between the dosage required for biological effect and the dosage 
for maximum effect without adverse effect of appetite. This will 
require prudent use by producers and recognition that “more is not 
better”.
As a consequence of the increased lean body mass, heat production 
resulting from basal metabolism increases 17 percent. This may re-
quire greater ventilation rates, particularly in warmer production en-
vironments.
Pale-soft-exudative pork is a meat quality problem of the pork in-
dustry which is associated with a lethal genetic disorder known as por-
cine stress syndrome. Treatment of hogs with PST results in a paler 
pork as judged from instrumental appraisal. Whether this is a true 
form of pale-soft-exudative pork is debatable. No indication of por-
cine stress syndrome resulting from the use of PST has been noted. A 
slight decrease of meat tenderness reported as a result of PST could 
relate to the mechanism of action; animals are physiologically less 
mature.
Some critics have implied that growth promotants, particularly 
PST and BST, will compromise the immunocompetence of the treated 
animal. Few studies have addressed this issue, but one report found 
PST to increase macrophage function such that immune system func-
tion would be enhanced. Theoretically this would decrease the risk of 
disease in treated hogs.
The major deterrent to the adoption of PST at present is the deve-
lopment and refinement of a drug delivery system. Ideally, this deliv-
ery device would be implantable with the capability of delivering the 
peptide for a 30 day period in a pulsatile manner, cycling every 24 
hours. This is a major bioengineering challenge which is actively being 
investigated by several companies.
CONCLUSION
PST, as well as BST, is not a doomsday technology designed to create 
meat animals of monstrous proportions. Agricultural research efforts 
are not directed at an increase of livestock population numbers. The 
objective of somatotropin as a technological advancement is to im-
prove the quality of the meat product so that consumer acceptability is 
improved and simultaneously improves production efficiency. PST 
clearly meets these objectives.
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